Macfarlanes advises PJT Partners in respect of $28bn take-private of Horizon Therapeutics plc by Amgen Inc

12 December 2022

Macfarlanes has advised investment banking company PJT Partners in connection with the recommended cash offer for Horizon Therapeutics plc by Amgen Inc.

The transaction implies an enterprise value of approximately $28bn for Horizon Therapeutics plc.

PJT Partners acted as lead financial adviser to Amgen Inc. The transaction is subject to certain conditions and is expected to complete in the first half of 2023.

The Macfarlanes team was led by corporate and M&A partner Tim Redman and finance partner Kirstie Hutchinson, with assistance from corporate and M&A senior associate Dennis Mok and finance associate Owen Giles.